This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Biogen Idec, Elan Corporation plc.New Pharmacoeconomic Data on TYSABRI (Rm) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis. Media Release: 7 Oct 2006. Available from: URL: http://www.biogenidec.com
Rights and permissions
About this article
Cite this article
Natalizumab shows clinical, cost and QOL benefits. Pharmacoecon. Outcomes News 514, 1 (2006). https://doi.org/10.2165/00151234-200605140-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605140-00001